Market Overview

UPDATE: Morgan Stanley Upgrades Alkermes plc to Overweight on New Pipeline Opportunities

Share:
Related ALKS
Recro's Late-Stage IV Meloxicam Trial Results Rocket Stock Skyward
Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock
Recro Pharma amends agreement with Alkermes increasing a milestone payment if deferred (Seeking Alpha)

Morgan Stanley upgraded Alkermes plc (NASDAQ: ALKS) from Equal-weight to Overweight and raised the price target from $21.00 to $26.00.

Morgan Stanley noted, "We anticipate improving investor perception as Alkermes transitions from being an outsourced drug delivery tech co. to an innovation engine with higher-value internal candidates. … We added a key new pipeline drug (3831 for schizophrenia) due to new disclosure Jan. 4, and we have greater conviction that Alkermes can develop new drugs to offset patent expirations in 2019 and beyond."

Alkermes plc closed at $21.61 on Wednesday.

Latest Ratings for ALKS

DateFirmActionFromTo
Oct 2016JP MorganUpgradesNeutralOverweight
Oct 2016Leerink SwannAssumesOutperform
Sep 2016CitigroupMaintainsNeutral

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ALKS)

View Comments and Join the Discussion!